Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely cover mechanism and dosing with some accuracy, but include multiple assertions not supported by the label (e.g., rapid onset, STEP/MOUNJARO data, cross-drug comparisons). Several supported points align with the label (GLP-1 mechanism, titration to mitigate GI effects, observed nausea rates, gradual weight-loss trends, and the influence of GI events on perceived benefits). Overall, partial alignment with notable misattributions and unsupported timing/course claims.
Category Scores
Accurate Statements
The effect is driven by activation of GLP-1 receptors in the brain's hunger centers.
12.1, 12.2
Starting at 0.25 mg weekly ramps slowly to minimize nausea.
2.2
There is an average 15-20% weight loss tied to ongoing appetite control.
14.2
Lower starter doses (0.25-0.5 mg) act slower than maintenance (2.4 mg).
2.2
Slower if gastrointestinal side effects dominate early.
6.1, 12.2
Nausea hits 44% in week 1.
6.1
Nausea fades by week 4 for most.
6.1, 12.2
Diarrhea or vomiting can delay noticing benefits.
6.1, 12.2
Unsupported Statements
Wegovy starts suppressing appetite within hours of the first dose.
Label describes gradual titration; no onset within hours.
Clinical data show peak appetite-reducing effects around 1-2 days after subcutaneous injection.
Time course not described as such in label.
In STEP trials, about 70% of participants experienced reduced hunger by day 3-5.
No STEP trial timing with hunger reduction is described in label.
Average daily calorie intake dropped 20-30% by week 1.
Label does not provide such a figure by week 1.
Full appetite control is delayed to week 4-5 at 1-2.4 mg doses.
No fixed week-4/5 endpoint for full appetite control is stated.
Early responders feel it in 24-48 hours; others take up to 7 days.
No such early-responders timing is described in label.
Full effects peak at 4-8 weeks, once therapeutic levels stabilize.
Label indicates gradual effects; no explicit peak at 4-8 weeks.
Long-term data from SUSTAIN trials confirm sustained suppression for 68+ weeks.
SUSTAIN trials pertain to tirzepatide (Mounjaro), not Wegovy; misattribution.
Missing doses can rebound hunger within days.
Label does not explicitly state rebound hunger after missed doses.
Faster in those with higher BMI or insulin resistance.
Label does not specify differential onset by BMI/insulin resistance.
Effects strongest 4-6 hours post-injection, lasting a week.
No such rapid on/off timing described.
Pairing with a low-calorie diet amplifies perceived suppression immediately.
Label notes diet pairing but not immediate amplification.
Wegovy (2.4 mg weekly) matches Ozempic's (up to 2 mg) onset but sustains stronger suppression due to higher dosing.
Label does not compare Wegovy to Ozempic onset.
Mounjaro (tirzepatide) acts faster—appetite drop in 1 day for many—via dual GLP-1/GIP action, though head-to-head trials show similar week-4 results.
Mounjaro-related data pertain to tirzepatide, not Wegovy; not in label.
Contradictions
Low
AI Statement
Long-term data from SUSTAIN trials confirm sustained suppression for 68+ weeks.
Label Reference
14.2
Important Omissions
Cardiovascular outcomes / CV risk reduction data
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Reported adverse events and monitoring considerations align with label; no new safety signals identified in the evaluated claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims are unsupported or misattributed (e.g., rapid onset, STEP/MOUNJARO data, cross-drug comparisons) and could mislead safety/effectiveness expectations.
Suggested Improvement
Restrict statements to label-supported pharmacodynamics, dosing/titration, adverse events (notable rates), and duration of effect; avoid cross-drug comparisons or non-labeled time-course claims.